Impact of clinical awareness and diagnostic tests on the underdiagnosis of Clostridium difficile infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 8, 2015, Pages 1515-1525

  Alcala L ^a,c,d   Reigadas, E ^a,b,c   Marin M ^a,b,c,d   Martin A ^a   Catalan P ^a   Bouza, E ^a,b,c,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DAPTOMYCIN; GATIFLOXACIN; LINEZOLID; METRONIDAZOLE; MOXIFLOXACIN; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC TEST; FECES ANALYSIS; FECES CULTURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEGLECTED DISEASE; PRIORITY JOURNAL; UNDERDIAGNOSIS; ADOLESCENT; AWARENESS; CHEMICALLY INDUCED; CHILD; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; DIAGNOSTIC ERROR; DIARRHEA; GOOD LABORATORY PRACTICE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; PROCEDURES; SPAIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AWARENESS; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIAGNOSTIC ERRORS; DIAGNOSTIC TESTS, ROUTINE; DIARRHEA; FEMALE; HUMANS; LABORATORY PROFICIENCY TESTING; MALE; MIDDLE AGED; SPAIN; YOUNG ADULT;

EID: 84937972102     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2380-3     Document Type: Article

References (36)

1. Riley TV, Cooper M, Bell B, Golledge CL (1995) Community-acquired Clostridium difficile-associated diarrhea. Clin Infect Dis 20(Suppl 2):S263–S265
2. McFarland LV, Mulligan ME, Kwok RY, Stamm WE (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320(4):204–210. doi:10.1056/NEJM198901263200402
3. Alcalá L, Sánchez-Cambronero L, Catalán MP, Sánchez-Somolinos M, Peláez MT, Marín M, Bouza E (2008) Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens. J Clin Microbiol 46(11):3833–3835. doi:10.1128/JCM.01060-08
4. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M, Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group (2011) Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377(9759):63–73. doi:10.1016/S0140-6736(10)61266-4
5. Alcalá L, Martín A, Marín M, Sánchez-Somolinos M, Catalán P, Peláez T, Bouza E; Spanish Clostridium difficile Study Group (2012) The undiagnosed cases of Clostridium difficile infection in a whole nation: where is the problem? Clin Microbiol Infect 18(7):E204–E213. doi:10.1111/j.1469-0691.2012.03883.x
6. Alcalá L, Marín M, Madrid M, Domínguez-García E, Catalán P, Peláez MT, Sánchez-Somolinos M, Bouza E (2010) Comparison of ImmunoCard Toxins A&B and the new semiautomated Vidas Clostridium difficile Toxin A&B tests for diagnosis of C. difficile infection. J Clin Microbiol 48(3):1014–1015. doi:10.1128/JCM.01642-09
7. Bouza E, Marín M, Peláez T, Alcalá L; Group for Clostridium difficile Infection of the Spanish Society for Chemotherapy (2013) The situation and management of Clostridium difficile infection in Spain: an opinion document. Rev Esp Quimioter 26(3):261–286
8. Stubbs SL, Brazier JS, O’Neill GL, Duerden BI (1999) PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37(2):461–463
9. Spigaglia P, Mastrantonio P (2002) Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40(9):3470–3475
10. Persson S, Torpdahl M, Olsen KE (2008) New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect 14(11):1057–1064. doi:10.1111/j.1469-0691.2008.02092.x
11. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 4.0, 2014. http://www.eucast.org
12. Clinical and Laboratory Standards Institute (CLSI) (2007) Methods for antimicrobial susceptibility testing of anaerobic bacteria; Approved standard—Seventh edition. CLSI document M11-A7. CLSI, Wayne, PA
13. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delmée M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio P, von Müller L, Oleastro M, Petinaki E, Pituch H, Norén T, Nováková E, Nyč O, Rupnik M, Schmid D, Wilcox MH (2014) Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14(12):1208–1219. doi:10.1016/S1473-3099(14)70991-0
14. Gilca R, Fortin E, Frenette C, Longtin Y, Gourdeau M (2012) Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada. Antimicrob Agents Chemother 56(2):639–646. doi:10.1128/AAC.05411-11
15. Brown KA, Daneman N, Arora P, Moineddin R, Fisman DN (2013) The co-seasonality of pneumonia and influenza with Clostridium difficile infection in the United States, 1993–2008. Am J Epidemiol 178(1):118–125. doi:10.1093/aje/kws463
16. Bouza E, Peláez T, Alonso R, Catalán P, Muñoz P, Créixems MR (2001) “Second-look” cytotoxicity: an evaluation of culture plus cytotoxin assay of Clostridium difficile isolates in the laboratory diagnosis of CDAD. J Hosp Infect 48(3):233–237. doi:10.1053/jhin.2001.1000
17. Tenover FC, Baron EJ, Peterson LR, Persing DH (2011) Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn 13(6):573–582. doi:10.1016/j.jmoldx.2011.06.001
18. Vasoo S, Stevens J, Portillo L, Barza R, Schejbal D, Wu MM, Chancey C, Singh K (2014) Cost-effectiveness of a modified two-step algorithm using a combined glutamate dehydrogenase/toxin enzyme immunoassay and real-time PCR for the diagnosis of Clostridium difficile infection. J Microbiol Immunol Infect 47(1):75–78. doi:10.1016/j.jmii.2012.07.008
19. Wilcox MH, Planche T, Fang FC, Gilligan P (2010) What is the current role of algorithmic approaches for diagnosis of Clostridium difficile infection? J Clin Microbiol 48(12):4347–4353. doi:10.1128/JCM.02028-10
20. Quinn CD, Sefers SE, Babiker W, He Y, Alcabasa R, Stratton CW, Carroll KC, Tang YW (2010) C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol 48(2):603–605. doi:10.1128/JCM.01614-09
21. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18. doi:10.1111/j.1469-0691.2006.01580.x
22. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR (2012) The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107(1):89–95. doi:10.1038/ajg.2011.398
23. Dumyati G, Stevens V, Hannett GE, Thompson AD, Long C, Maccannell D, Limbago B (2012) Community-associated Clostridium difficile infections, Monroe County, New York, USA. Emerg Infect Dis 18(3):392–400. doi:10.3201/eid1803.102023
24. Naggie S, Frederick J, Pien BC, Miller BA, Provenzale DT, Goldberg KC, Woods CW (2010) Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA. Infection 38(4):297–300. doi:10.1007/s15010-010-0025-0
25. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM (2011) Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case–control study. BMC Infect Dis 11:194. doi:10.1186/1471-2334-11-194
26. Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J, McDonald LC (2010) Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 16(2):197–204. doi:10.3201/eid1602.090953
27. Karlström O, Fryklund B, Tullus K, Burman LG (1998) A prospective nationwide study of Clostridium difficile-associated diarrhea in Sweden. The Swedish C difficile Study Group. Clin Infect Dis 26(1):141–145
28. van den Berg RJ, Ameen HA, Furusawa T, Claas EC, van der Vorm ER, Kuijper EJ (2005) Coexistence of multiple PCR-ribotype strains of Clostridium difficile in faecal samples limits epidemiological studies. J Med Microbiol 54(Pt 2):173–179
29. Tanner HE, Hardy KJ, Hawkey PM (2010) Coexistence of multiple multilocus variable-number tandem-repeat analysis subtypes of Clostridium difficile PCR ribotype 027 strains within fecal specimens. J Clin Microbiol 48(3):985–987. doi:10.1128/JCM.02012-09
30. Marín M, Martín A, Alcolea A, Iglesias C, Alcalá L, Peláez T, Sánchez-Somolinos M, Bouza E (2014) First case of autochthonous Clostridium difficile PCR ribotype 027 detected in Spain. Enferm Infecc Microbiol Clin 32(6):355–358. doi:10.1016/j.eimc.2013.07.004
31. Bouza E, Martin A, Van den Berg RJ, Kuijper EJ (2008) Laboratory-acquired Clostridium difficile polymerase chain reaction ribotype 027: a new risk for laboratory workers? Clin Infect Dis 47(11):1493–1494. doi:10.1086/593109
32. Barbut F, Decré D, Burghoffer B, Lesage D, Delisle F, Lalande V, Delmée M, Avesani V, Sano N, Coudert C, Petit JC (1999) Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 43(11):2607–2611
33. Brazier JS, Fawley W, Freeman J, Wilcox MH (2001) Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 48(5):741–742
34. Peláez T, Cercenado E, Alcalá L, Marín M, Martín-López A, Martínez-Alarcón J, Catalán P, Sánchez-Somolinos M, Bouza E (2008) Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 46(9):3028–3032. doi:10.1128/JCM.00524-08
35. Wong SS, Woo PC, Luk WK, Yuen KY (1999) Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 34(1):1–6
36. Keighley MR, Burdon DW, Arabi Y, Williams JA, Thompson H, Youngs D, Johnson M, Bentley S, George RH, Mogg GA (1978) Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 2(6153):1667–1669